The relationship between nonsteroidal anti-inflammatory drugs and cancer incidence: An umbrella review
Puze Wang,Bo Chen,Yin Huang,Jin Li,Dehong Cao,Zeyu Chen,Jinze Li,Biao Ran,Jiahao Yang,Ruyi Wang,Qiang Wei,Qiang Dong,Liangren Liu
DOI: https://doi.org/10.1016/j.heliyon.2023.e23203
IF: 3.776
2024-01-01
Heliyon
Abstract:Several clinical and preclinical studies have shown that nonsteroidal anti-inflammatory drugs (NSAIDs), particularly aspirin, reduce the incidence of various cancer types. However, there is still a lack of literature evaluating the overall association between multiple cancer morbidities and NSAIDs. Thus, we conducted an umbrella review to evaluate the quality of evidence, validity, and biases of the existing systematic reviews and meta -analyses on the relationships between NSAIDS and multiple tumor incidence outcomes. We found that NSAIDs might be associated with a decreased risk of several cancers, including the central nervous system, breast, esophageal, gastric, head and neck, hepatocellular, cholangiocarcinoma, colorectal, endometrial, lung, ovary, prostate, and pancreatic cancers, but regular intake of any dose of non -aspirin NSAIDs (NANSAIDs) could increase the incidence of kidney cancer. However, most of included studies are evaluated as low quality according to our evidence assessment. Furthermore, due to the potential side effects, such as hemorrhage, digestive symptoms and peptic ulcer, it is still not recommend to use NSAIDs regularly to prevent cancers.